scholarly journals Transcriptional Profiling Reveals Strong Impact of Major Molecular Disease Subgroups and Mixed Epistasis in Chronic Lymphocytic Leukemia

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 1742-1742
Author(s):  
Thorsten Zenz ◽  
Almut Luetge ◽  
Junyan Lu ◽  
Huellein Jennifer ◽  
Sascha Dietrich ◽  
...  

While recurrent mutations in CLL have been extensively catalogued, how driver mutations affect disease phenotypes remains incompletely understood. To address this, we performed RNA sequencing on 184 CLL patient samples and linked gene expression changes to molecular subgroups, gene mutations and copy number variants. Library preparation was performed according to the Illumina TruSeq RNA sample preparation v2 protocol. Samples were paired-end sequenced and two to three samples were multiplexed per lane on Illumina HiSeq 2000, Illumina HiSeq3000/4000 or Illumina HiSeqX machines. Raw RNA-seq reads were demultiplexed and quality control was performed using FastQC version 0.11.5. Internal trimming with STAR version 2.5.2a was used to remove adapters before mapping. Mapping was performed using STAR version 2.5.2a against the Ensembl human reference genome release 75 (Homo sapiens GRCh37.75). STAR was run in default mode with internal adapter trimming using the clip3pAdapterSeq option. Mapped reads were summarized into counts using htseq-count version 0.9.0 with default parameters and union mode. Thus, only fragments unambiguously overlapping with one gene were counted. The count data were then imported into R (version 3.4) for subsequent analysis. We identified robust and previously unknown gene expression signatures associated with recurrent copy number variants (including trisomy 12, del11q22.3, del17p13, del18p12 and gain8q24), gene mutations (TP53, BRAF and SF3B1) and the mutation status of the immunoglobulin heavy-chain variable region (IGHV). The most profound gene expression changes were associated with IGHV, methylation groups and trisomy 12. We found evidence for a significant influence of CNVs beyond the gene dosage effect. In line with these observations, unsupervised clustering showed that these major biological subgroups form distinct clusters and are discernible by unsupervised clustering (IGHV, methylation groups and trisomy 12). We found 3275 genes significantly differentially expressed between M-CLL and U-CLL after adjustment for multiple testing using the method of Benjamini and Hochberg for FDR = 1% . In total 9.5 % of variance within gene expression was associated with the IGHV status. These data suggest a much larger impact on transcriptional changes than previously detected (Ferreira et al. 2014), a finding much more in line with the key impact of IGHV on clinical course and biology of disease. We found distinct expression pattern of up- and downregulated genes for trisomy 12 samples. Even though many upregulated genes are located on chromosome 12, the majority of differentially expressed genes are indeed distributed among the other chromosomes and cannot be therefore not be ascribed to a simple gene dosage effect. To investigate the role of genetic interactions, we tested the collaborative effect on gene expression phenotypes. We investigated epistatic gene expression changes for IGHV status and trisomy 12. Epistasis was defined as a non-linear effect on gene expression between sample with both variants co-occuring and the single variants alone. In total 893 genes showed specific expression pattern in a combined genotype (padj<0.1). These expression changes differed from the expected change by simple combination of the single variant's effects. We observed different ways of epistatic interaction and clustered genes by them. In total, we identified five cluster of genes representing different ways of mixed epistasis as inversion down, suppression, different degrees of buffering and inversion up. To further investigate this interaction we used enrichment tests for genes in the different mixed epistasis cluster. We found genes upregulated in trisomy12 U-CLL sample, but suppressed in M-CLL trisomy12 samples were enriched in Wnt beta catenin and Notch signaling. In summary, our study provides a comprehensive reference data set for gene expression in CLL. We show that IGHV mutation status, recurrent gene mutations and CNVs drive gene expression in a previously underappreciated fashion. This includes epistatic interaction between trisomy 12 and IGHV. Using a novel way to describe coordinated changes we can group genes into sets related to buffering, inversion and suppression. Disclosures Sellner: Takeda: Employment.

2020 ◽  
Vol 13 (1) ◽  
Author(s):  
Maria Yamasaki ◽  
Takashi Makino ◽  
Seik-Soon Khor ◽  
Hiromi Toyoda ◽  
Taku Miyagawa ◽  
...  

2018 ◽  
Vol 3 (1) ◽  
Author(s):  
Mark A. Corbett ◽  
Clare L. van Eyk ◽  
Dani L. Webber ◽  
Stephen J. Bent ◽  
Morgan Newman ◽  
...  

2020 ◽  
Vol 105 (7) ◽  
pp. 2392-2400
Author(s):  
Rebecca J Gordon ◽  
Dong Li ◽  
Daniel Doyle ◽  
Joshua Zaritsky ◽  
Michael A Levine

Abstract Context Hypophosphatemia and metabolic bone disease are associated with hereditary hypophosphatemic rickets with hypercalciuria (HHRH) due to biallelic mutations of SLC34A3 encoding the NPT2C sodium-phosphate cotransporter and nephrolithiasis/osteoporosis, hypophosphatemic 1 (NPHLOP1) due to monoallelic mutations in SLC34A1 encoding the NPT2A sodium-phosphate cotransporter. Objective To identify a genetic cause of apparent dominant transmission of HHRH. Design and Setting Retrospective and prospective analysis of clinical and molecular characteristics of patients studied in 2 academic medical centers. Methods We recruited 4 affected and 3 unaffected members of a 4-generation family in which the proband presented with apparent HHRH. We performed clinical examinations, biochemical and radiological analyses, and molecular studies of genomic DNA. Results The proband and her affected sister and mother carried pathogenic heterozygous mutations in 2 related genes, SLC34A1 (exon 13, c.1535G&gt;A; p.R512H) and SLC34A3 (exon 13, c.1561dupC; L521Pfs*72). The proband and her affected sister inherited both gene mutations from their mother, while their clinically less affected brother, father, and paternal grandmother carried only the SLC34A3 mutation. Renal phosphate-wasting exhibited both a gene dosage–effect and an age-dependent attenuation of severity. Conclusions We describe a kindred with autosomal dominant hypophosphatemic rickets in which whole exome analysis identified digenic heterozygous mutations in SLC34A1 and SLC34A3. Subjects with both mutations were more severely affected than subjects carrying only one mutation. These findings highlight the challenges of assigning causality to plausible genetic variants in the next generation sequencing era.


2010 ◽  
Vol 426 (2) ◽  
pp. 119-123 ◽  
Author(s):  
James A. Birchler

Aneuploidy involves changes in chromosomal copy number compared with normal euploid genotypes. Studies of gene expression in aneuploids in a variety of species have claimed many different types of responses. Studies of individual genes suggest that there are both structural gene dosage effects and compensation in aneuploids, and that subtle trans-acting effects across the genome are quite prevalent. A discussion is presented concerning the normalization procedures for studying gene expression in aneuploids. A careful documentation of the modulations of gene expression in aneuploids should provide insight into the nature of cancerous cells and the basis of aneuploid syndromes.


Blood ◽  
2005 ◽  
Vol 106 (11) ◽  
pp. 1538-1538
Author(s):  
Wee-Joo Chng ◽  
Scott Van Wier ◽  
Gregory Ahmann ◽  
Tammy Price-Troska ◽  
Kim Henderson ◽  
...  

Abstract Hyperdiploid MM (H-MM), characterized by recurrent trisomies constitute about 50% of MM, yet very little is known about its pathogenesis and oncogenic mechanisms. Studies in leukemia and solid tumors have shown gene dosage effect of aneuploidy on gene expression. To determine the possible gene dosage effect and deregulated cellular program in H-MM we undertook a gene expression study of CD138-enriched plasma-cell RNA from 53 hyperdiploid and 37 non-hyperdiploid MM (NH-MM) patients using the Affymetrix U133A chip (Affymetrix, Santa Clara, CA). Gene expression data was analyzed using GeneSpring 7 (Agilent Technologies, Palo Alto, CA). Genes differentially expressed between H-MM and NH-MM were obtained by t-test (p&lt;0.01). The majority of the differentially expressed genes (57%) were under-expressed in H-MM. Genes located on the commonly trisomic chromosomes were mostly (but not always) over-expressed in H-MM and constitute 76% of over-expressed genes. Chromosome 1 contained the most differentially expressed genes (17%) followed by chromosome 12 (9%), and 19 (8%). To examine the relationship of gene copy number to gene expression, we examined the expression of genes on chromosomes 9 and 15 in subjects with 2 copies (15 normal control and 20 NH-MM) and 3 copies (12 H-MM) of each chromosome as detected by interphase FISH. We then derived a ratio of the mean expression of each gene on these chromosomes between patients with 3 copies and 2 copies of the chromosome. If a simple relationship exists between gene expression and gene copy number, one would expect the ratio of expression of most genes on these two chromosomes to be about 1.5 in H-MM compared to NH-MM. However, many genes have ratios either higher than 2 or lower than 0.5. Furthermore, when the heterogeneity of cells with underlying trisomies is taken into consideration by correcting the ratio for the number of cells with trisomies, the actual ratio is always lower than the expected ratio. When the expression of genes on a chromosome was compressed to a median value, this value was always higher in the trisomic chromosomes for H-MM compared to NH-MM. The data suggests that although gene dosage influence gene expression, the relationship is complex and some genes are more gene dosage dependent than others. Amongst the differentially expressed genes with known function, 33% are involved in mRNA translation/protein synthesis. Of note, 37 of the top 100 differentially expressed genes are involved in these processes. In particular, 60 ribosomal protein (RP) genes are significantly (p&lt;0.05) upregulated in H-MM. This signature in H-MM is not associated with increase proliferation as measured by PCLI. This predominant signature suggests that deregulated protein synthesis may be important for the biology of H-MM. Many of these RPs are involved in the synthesis of product of oncogenic pathways (e.g. MYC, NF-KB pathways) and may mediate the growth and survival of tumor cells. It is therefore possible that these tumor cells may be sensitive to the disruption of mRNA translation/protein synthesis. Targeting the mTOR pathway with rapamycin may therefore be useful for treatment of H-MM.


2010 ◽  
Vol 64 (3) ◽  
pp. 200-207 ◽  
Author(s):  
Kathleen Lambein ◽  
Marleen Praet ◽  
Ramses Forsyth ◽  
Rudy Van den Broecke ◽  
Geert Braems ◽  
...  

AimsA few reports have assessed HER2 status in breast cancer by both dual-probe fluorescence in situ hybridisation (FISH) and immunohistochemistry (IHC) in an unselected and consecutive fashion, but CEP17 and HER2 copy number were not evaluated separately in these studies. Therefore, the aim of this study was to perform FISH testing for HER2 in a large number of breast tumours, irrespective of the IHC scores, which were also determined in all cases.MethodsBoth FISH and IHC were applied to 200 tumours from 196 consecutive patients who underwent resection of primary breast cancer with the sentinel procedure and/or axillary dissection. Not only the ratio, but also mean HER2 and CEP17 copy number were determined and used in statistical analyses to evaluate relationships between FISH, IHC and clinicopathological features.ResultsThe amplification status based solely on HER2 signals was 98% concordant with results of dual-probe FISH. In non-amplified tumours, the mean CEP17 and HER2 copy number correlated, possibly because of cell cycling. Amplified tumours were histopathologically more aggressive than non-amplified tumours, and features of aggressiveness increased with the mean HER2 copy number. In both amplified and non-amplified tumours, a gene dosage effect was observed: an increase in the mean HER2 copy number was associated with a higher IHC score.ConclusionsThis working method and analysis enabled new insights to be obtained into the pathobiology of HER2 in breast cancer. The findings may be helpful in optimising the methodology of HER2 testing.


2017 ◽  
Vol 71 (4) ◽  
pp. 372-378 ◽  
Author(s):  
Wei Shen ◽  
Christian N Paxton ◽  
Philippe Szankasi ◽  
Maria Longhurst ◽  
Jonathan A Schumacher ◽  
...  

AimsGenetic abnormalities, including copy number variants (CNV), copy number neutral loss of heterozygosity (CN-LOH) and gene mutations, underlie the pathogenesis of myeloid malignancies and serve as important diagnostic, prognostic and/or therapeutic markers. Currently, multiple testing strategies are required for comprehensive genetic testing in myeloid malignancies. The aim of this proof-of-principle study was to investigate the feasibility of combining detection of genome-wide large CNVs, CN-LOH and targeted gene mutations into a single assay using next-generation sequencing (NGS).MethodsFor genome-wide CNV detection, we designed a single nucleotide polymorphism (SNP) sequencing backbone with 22 762 SNP regions evenly distributed across the entire genome. For targeted mutation detection, 62 frequently mutated genes in myeloid malignancies were targeted. We combined this SNP sequencing backbone with a targeted mutation panel, and sequenced 9 healthy individuals and 16 patients with myeloid malignancies using NGS.ResultsWe detected 52 somatic CNVs, 11 instances of CN-LOH and 39 oncogenic mutations in the 16 patients with myeloid malignancies, and none in the 9 healthy individuals. All CNVs and CN-LOH were confirmed by SNP microarray analysis.ConclusionsWe describe a genome-wide SNP sequencing backbone which allows for sensitive detection of genome-wide CNVs and CN-LOH using NGS. This proof-of-principle study has demonstrated that this strategy can provide more comprehensive genetic profiling for patients with myeloid malignancies using a single assay.


2015 ◽  
Vol 22 (12) ◽  
pp. 1907-1910 ◽  
Author(s):  
Dong Wang ◽  
Xia Li ◽  
Shanshan Jia ◽  
Yan Wang ◽  
Zhijing Wang ◽  
...  

2021 ◽  
Author(s):  
Luka Culibrk ◽  
Jasleen K Grewal ◽  
Erin D Pleasance ◽  
Laura Williamson ◽  
Karen Mungall ◽  
...  

Cancers routinely exhibit chromosomal instability, resulting in the accumulation of changes in the abundance of genomic material, known as copy number variants (CNVs). Unfortunately, the detection of these variants in cancer genomes is difficult. We developed Ploidetect, a software package that effectively identifies CNVs within whole-genome sequenced tumors. Ploidetect was more sensitive to CNVs in cancer related genes within advanced, pre-treated metastatic cancers than other tools, while also segmenting the most contiguously. Chromosomal instability, as measured by segment contiguity, was associated with several biological and clinical variables, including tumor mutation burden, tumor type, duration of therapy and immune microenvironment, highlighting the relevance of measuring CNV across the cancer genome. Investigation of gene mutations in samples revealed and the mutation status of several genes including ROCK2 and AC074391.1. Leveraging our heightened ability to detect CNVs, we identified 282 genes which were recurrently homozygously deleted in metastatic tumors. Further analysis of one recurrently deleted gene, MACROD2, identified a putative fragile tumor suppressor locus associated with response to chromosomal instability and chemotherapeutic agents. Our results outline the multifaceted impacts of CNVs in cancer by providing evidence of their involvement in tumorigenic behaviors and their utility as biomarkers for biological processes. We propose that increasingly accurate determination of CNVs is critical for their productive study in cancer, and our work demonstrates advances made possible by progress in this regard.


Sign in / Sign up

Export Citation Format

Share Document